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Abstract: This review focuses on emerging viral and bacterial infections in the human central
nervous system (CNS) that are responsible for significant global morbidity and mortality.
These infections include those responsible for acute neurological disease such as meningitis
and encephalitis as well those associated with chronic neurodegenerative conditions. Recent
changes in climate conditions and pollution have been precipitating factors leading to the emergence of many of these pathogenic organisms. In addition, increased urbanization, global travel,
life span, and exposure to new vectors have promoted the organisms’ spread across the globe.
Categorization of many of these organisms includes identification of new species, recognition
of new tropism to the CNS, spread into naïve demographic areas, increased human contact with
zoonotic repositories including insect vectors, and reemergence of well-known organisms. These
mechanisms are highlighted for the different organisms included in this review. Other mechanisms for CNS emergence such as genetic mutation of the organisms and immunosuppression
and/or immunosenescence of the host are addressed. Viral and bacterial infections in chronic
neurodegenerative diseases traditionally not thought to be infectious are considered. Although
this review cannot be all-inclusive, the organisms included represent a sampling of extremely
important microbes and their role in CNS pathogenesis in the twenty-first century.
Keywords: viruses, bacteria, central nervous system, emergence

Global emergence of central nervous system (CNS) associated infectious disease
is currently being recognized. Pathogenic viruses, bacteria, fungi, and protozoa are
infecting the human CNS resulting in widespread disease. Global variances including climate changes and pollution have led to changes in these pathogenic organisms.
Increased human urbanization, global travel, and life span have led to increased exposure to drug-resistant viral and bacterial strains, as well as to new strains, often through
increased zoonotic and vector contact. This review focuses on viral and bacterial
infections in the CNS that are causing and/or associated with significant morbidity and
mortality in acute neurological disease and chronic neurodegenerative conditions.
As research is uncovering associations of viral and bacterial infections with major
CNS diseases traditionally not considered caused or exacerbated by infectious entities, we have included these as emerging infections. In this way, this review extends
our awareness and understanding of the involvement of infection in the concomitant
pathogenesis of CNS disease.

Viruses
Prior studies and reviews by others have highlighted many viruses (see Table 1)
contributing to the new emergence of infection in the human CNS.1–3 Categorization
Neurobehavioral HIV Medicine 2012:4 35–44
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of these viruses includes identif ication of new viral
species, recognition of new viral tropism to the CNS,
viral spread into naïve demographic areas, increased
human contact with zoonotic repositories including insect
vectors, and reemergence of well-known viral species.
Other mechanisms for CNS emergence include genetic
mutation of existing viruses and immunosuppression and/
or immunosenescence of the host. Some of these viruses
may be associated with specific disease states such as John
Cunningham virus (JC virus) and progressive multifocal
leukoencephalopathy, while others, like West Nile virus,
appear to play a role in meningitis, encephalitis, or
meningoencephalitis.

Identification of new viral species
Henipaviruses (Hendra and Nipah) in the family Paramyxoviridae were first identified in the mid to late 1990s.4,5
Hendra infection was first identified in the aseptic meningitis and frank encephalitis deaths of a few Australian
individuals who had been in close contact with horses.4
Hendra was originally thought to be an equine Morbillivirus but was subsequently reclassified with Nipah virus
into the Henipaviruses. Nipah virus is the more frequently
encountered virus of the H
 enipaviruses, and most cases of
emergence have resulted from this infection. Nipah was
identified originally in pig farmers in Malaysia in 1998 and
resulted in acute encephalitis that proved fatal in .30% of
cases.5,6 Common neurological symptoms include fever,
headache, segmental myoclonus, reduced tendon reflexes,
nuchal rigidity, and seizures.7,8 Interestingly, with Nipah
Table 1 Proposed viruses emerging in central nervous system
disease
Virus

Condition/disease
association

Viral family

Henipah virus
(Hendra and Nipah)
Enterovirus 71

Encephalitis/meningitis

Paramyxoviridae

Encephalitis/meningitis/
flaccid paralysis
Encephalitis/meningitis
Encephalitis

Picornaviridae

West Nile virus
Japanese
encephalitis virus
Chikungunya virus
Influenza virus
JC virus
Human
Herpesvirus 6
Herpes simplex
virus 1

36

Encephalitis/meningitis
Encephalitis/schizophrenia
Progressive Multifocal
Leukoencephalopathy (PML)
Encephalitis/epilepsy/
multiple sclerosis
Encephalitis/Alzheimer’s
disease
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Flaviviridae
Flaviviridae
Togaviridae
Orthomyxoviridae
Polyomaviridae
Herpesviridae
Herpesviridae

infection, 3% of individuals developed late-onset encephalitis that did not initially have neurological symptoms, and
8% of acute encephalitic patients had recurrent or relapsing encephalitis on an average of 8 months following acute
disease.9 Of the fatal cases of Nipah virus infection, analysis
of brain tissues at autopsy suggested the virus spreads to the
CNS from the bloodstream. Following this spread, there is
subsequent multifocal vasculitis, multicentric thrombosis,
and direct neuronal infection.10 Outbreaks of Nipah virus
encephalitis also have appeared in India and Bangladesh
with high mortality; however, these are thought to be mitigated by a different source of infection, secretions from the
fruit bat.11 Newer studies suggest that transmission now can
occur from person to person.12 Regardless of the mode of
transmission, infection with this family of viruses exacts
a large toll on the human population, thus keeping these
viruses near the top of emerging CNS infectious threats.
There is no effective treatment for these viruses other than
supportive care.

Viruses emerging in new
demographic areas
Numerous viruses have emerged recently in new demographic areas around the world. Some of the most notable
are Enterovirus 71, West Nile virus, Japanese encephalitis
virus, and Chikungunya virus. Interestingly, other than for
Enterovirus 71, one commonality of these viruses is that they
are insect vector borne.

Enterovirus 71
Enterovirus 71 (EV71) is a member of the family Picornaviridae
and is one of the most important regarding widespread
demographic emergence and involvement with CNS disease. This is particularly the case in children in which
hand-foot-mouth disease is manifest most often following
this infection.2 Brainstem encephalitis, acute flaccid paralysis, and aseptic meningitis have been recognized as sequelae
in these children, although this may vary with different
outbreaks.13,14 EV71 was first isolated in California in the
late 1960s, but since then there have been numerous outbreaks worldwide with some of the most severe occurring
in Southeast Asia and the Pacific Rim nations.15,16 During
hand-foot-mouth disease epidemics, CNS disease is frequently encountered, and symptoms may include systemic
features such as fever, mouth ulcers, cough, vomiting, and
irritability.17 Treatment for EV71 infections is principally
supportive. EV71 and mutated EV71 viruses appear to be
one of our greatest threats with emerging Picornaviridae,
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and thus, there is an increasing need for effective and specific
vaccines.15

West Nile virus
West Nile virus (WNV), a member of the Flaviviridae family,
was first isolated in the West Nile province of Uganda in the
1930s.2 The virus has been reported in Central America, the
Caribbean, Europe, the Middle East, Africa, India, Asia,
and Australia.18,19 No cases of WNV encephalitis were
recognized in the United States until the late 1990s yet the
virus has spread rapidly; today, most states have reported
cases of human disease.20,21 Culex genus mosquitos are the
principal vectors for WNV, and resident bird species are the
major host reservoir thought to be responsible for spread of
the virus.22 The majority of WNV infections are acute and
asymptomatic, with approximately 20% resulting in West
Nile Fever and approximately 1% leading to neuroinvasive
disease.23 Upon neuroinvasion, encephalitis, meningitis, and
acute flaccid paralysis may occur. Individuals 60 years of
age or older and afflicted with other conditions, including
diabetes and hypertension, are more susceptible to developing encephalitis.24 Encephalitis symptoms include mental
status change, headache, fever, and Parkinsonian movement
disorders. Meningitis symptoms typically consist of headache and fever, photophobia, and, at times, nerve palsies.
Individuals exhibiting acute flaccid paralysis also show
signs of encephalitis and Parkinsonism change with deficits
in nerve conduction; although some of these patients may
regain some strength over time, others may not recover.25
The clinical course is variable for WNV infections; patients
convalescing from meningitis may continue to have persistent headaches and fatigue, while those with encephalitis
may manifest persistent neurologic deficits.26 There is no
specific treatment other than supportive care for infected
individuals.

Japanese encephalitis virus
Similar to WNV, the Japanese encephalitis virus (JEV) is
a member of the Flaviviridae, and is transmitted by Culex
genus mosquitos.27 Natural reservoirs for this virus are
pigs, egrets, and herons. JEV was first identified in Japan
in the 19th century and has spread over decades into China,
Southeast Asia, India, and the Indian subcontinent, New
Guinea, and Australia.27 The emergence of JEV can be
attributed to increased population growth in endemic areas
and occupational exposure with rice and pig farming presenting increased risk of vector-borne infection.27 JEV often
is asymptomatic, but may cause severe acute encephalitis,
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which can be fatal.28 In this regard, 10,000 deaths or more
annually have been attributed to JEV infections and their role
in acute viral encephalitis.29,30 Symptoms range from nuchal
rigidity, severe rigors, and hemiparesis to nausea, headache,
and fever. Although there is no specific therapy for JEV, there
is a live-attenuated vaccine, and new candidate vaccines are
being developed.30

Chikungunya virus
Chikungunya virus (CHIKV), which belongs to the family
Togaviridae, is an arbovirus transmitted by the Aedes
mosquito (eg, Aedes aegypti). CHIKV was first isolated in
Tanzania and subsequently in other areas of sub-Saharan
Africa, India, and Southeast Asia.31 The virus is considered
an encephalitic and arthritic virus. Neurological diseases
attributed to CHIKV include encephalitis, meningitis,
encephalomyelitis, Guillain-Barré-like syndrome, and acute
flaccid paralysis.32–35 Experimental evidence from neonatal
and adult mice in which the interferon α/β receptor was
knocked out to prevent interferon signaling suggests that
virus inoculated peripherally may enter the choroid plexus
of the brain following a viremia.36 The association of this
virus with CNS disease in humans is thought to arise due to
increased geographical distribution by population mobility
from endemic areas to naïve areas and possibly by commercial trade of materials containing water-borne mosquito
larvae.37 In addition, there is evidence from an outbreak of
this infection on the island of La Reunion in the Indian Ocean
in 2005–2006 that the virus underwent mutation to infect
a second Aedes species, Aedes albopictus.31,38–41 As Aedes
albopictus mosquitos are found in urban areas of Europe and
the United States, there is increased risk for this infection to
spread in these areas.31,38 No specific antiviral treatment or
vaccine is currently available.

Genetic mutation of existing viruses
and immunosuppression
Influenza viruses

Influenza viruses typically are thought of as respiratory
disease–causing agents. However, their ability to undergo
genetic mutation, antigenic drift, and affect host development
as well as causing neurological symptoms suggests that they
will continue to emerge as infections in the CNS. Influenza
viruses are members of the family Orthomyxoviridae and
typically are associated with symptoms of the flu.42 However,
there can be neurological involvement as demonstrated during
epidemics, and potential involvement in neuropsychiatric
disorders following prenatal exposure. There have been
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reports of increasing incidence of influenza-associated
encephalitis/encephalopathy,43 especially in children infected
with influenza A (H1N1).44 Other clinical manifestations
also may be observed during or following influenza A infections, including Reye’s syndrome, myelitis, Guillain-Barré
syndrome, and acute necrotizing encephalopathy.43,44 Prenatal
influenza exposure also has been linked to the development
of schizophrenia through analysis of a birth cohort of the
Child Health and Development Study.45 Brown and colleagues used a case-control study based on this particular
cohort to determine that there was a threefold elevation in
risk for schizophrenia if there was exposure to influenza in
the first half of gestation.46 Interestingly, the elevation of risk
for schizophrenia was increased sevenfold when exposure
occurred within the first trimester, whereas no increase was
observed when influenza exposure occurred beyond the
second half of gestation. Thus, the vulnerable stage for risk
appears to be very early in gestation.46 What is not known at
this time is the specific mechanism accounting for this risk.
Investigations on influenza virus-infected pregnant mice
have analyzed specific cellular populations in the brains of
the offspring that appear to correlate in later life to decreased
exploratory and social behavior, decreased contact with new
objects in their environment, and an altered startle response
to noise.47,48 Of the cellular changes in the offspring, there
was a reduction in Cajal-Retzius cells in the cortex and hippocampus that were reelin-positive.47 Reelin is involved in
regulating neuronal migration and positioning of cells in the
developing brain.49 In the same mice, there was a decrease in
the cortical and hippocampal area but an increase in overall
cortical pyramidal cell density.47 These studies suggest that
influenza virus infection prenatally can have a dramatic result
on fetal brain development that may manifest as psychiatric
disease at later ages, although causality has yet to be proven
conclusively for this involvement. Furthermore, there appears
to be an increasing number of reported cases of neurologic
sequelae following influenza epidemics.50 Often there is no
specific treatment for infected individuals, although a number of drugs could be used to help treat and prevent the flu
such as oseltamivir (Tamiflu®; Hoffman-La Roche, Basel,
Switzerland) and zanamivir (Relenza®; GlaxoSmithKline,
London, UK).51

JC virus
JC virus is a member of the Polyomaviridae family and causes
progressive multifocal leukoencephalopathy (PML), a fatal
neurological disease. This disease is observed principally in
immunosuppressed or immunocompromised individuals who
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have low levels of cell-mediated immunity. In this regard,
other infections such as those with human immunodeficiency
virus (HIV) that result in an immunocompromised state
as well as drug therapy for autoimmune diseases such as
Crohn’s, multiple sclerosis, and rheumatoid arthritis promote
an increased incidence of PML.52–55 As high percentages
of the human population carry antibodies reactive to the
JC virus, the virus is thought to reside latently in the body,
systemically and in the CNS.56 Upon immunosuppression,
reactivation of the virus is thought to occur leading to death
of oligodendrocytes and destruction of myelin sheaths in the
CNS. Neurological symptoms include weakness, paralysis,
vision loss, impaired speech, and cognitive deterioration.56
Thus, serious consideration must be made for individuals
electing to be treated with many of the newer monoclonal
antibody treatments such as natalizumab for Crohn’s disease
resulting in variable degrees of immunosuppression.54

Herpes viruses
Herpes virus associated with immunocompetent individuals is
human herpesvirus 6 (HHV6), a member of the Herpesviridae
family. There are two variants (HHV6A and HHV6B).
HHV6A is thought to be overall more virulent and neurotropic, although HHV6B is found significantly in CNS disease.57
For example, HHV6B is commonly found in childhood and
has been associated with exanthem subitum (roseola infantum) and meningoencephalitis.58,59 HHV6B also has been
associated with infantile febrile illness with documented
seizures.60 Interestingly, HHV6B has been associated more
recently with fatal encephalitis in a number of cases following
hematopoietic stem cell transplantation.61 Further, studies
have found evidence of HHV6B in mesial temporal lobe
epilepsy62,63 and multiple sclerosis.64 However, conclusive
disease association with this virus in these diseases awaits
further investigation as there is evidence of HHV6 variants
in infection in normal human brain tissues.65 Commonly,
the limbic areas of the brain were affected, including the
amygdala, entorhinal cortex, and hippocampus, leading to
a designation of posttransplant acute limbic encephalitis.61
Ongoing research is investigating the roles of excitatory
amino acids and inflammation in the pathological processes
associated with HHV6 infection in the CNS.63,66 There is no
specific treatment for HHV6 infections, but drugs used to
treat other herpes infections (eg, ganciclovir) have been tried
in severe infections.67
Herpes simplex virus 1 (HSV1) is another member of
the Herpesviridae family. This virus is ubiquitous and often
found latent in peripheral trigeminal ganglion neurons.
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HSV1 may traffic into the CNS proper where the virus may
remain latent or reactivate; reactivation can result in serious
acute encephalitis of the frontotemporal region of the brain
in rare cases.68 Regarding neurodegenerative disease, in
particular Alzheimer’s disease (AD), studies have linked
CNS viral infection to AD by analyzing HSV1 DNA in
the brain,69–71 and anti-HSV1 antibodies in the CSF and
sera of patients with AD.71,72 Furthermore, HSV1 has been
correlated to the apolipoprotein E ε4 risk for AD,73 and shown
to bind to the amyloid precursor protein.74 HSV1 had been
demonstrated to code for a protein kinase involved with the
phosphorylation of the tau protein.75,76 More recently, the
virus has been shown to impair the autophagy pathway in
cells infected in vitro.77 Thus, although great strides have been
made in correlating this infection to the neurodegenerative
process, ongoing and future studies must continue to focus
on the mechanistic underpinnings of infection leading to the
emerging nature of HSV1 in AD. With regard to potential
therapy in AD, a recent study found that anti-HSV1 antiviral
agents reduced Aβ and phosphorylated tau accumulations in
HSV1-infected cells in vitro.78 Thus, potentially, anti-HSV1
antiviral therapy could be used in HSV1-associated AD.

Bacteria
Emergence of bacterial infections in the CNS has been
demonstrated (see Table 2). This review highlights some of
the intracellular and extracellular bacteria contributing to
disease in the CNS. Many of these bacteria use specific entry
mechanisms into the CNS similar to those used by numerous viruses, including bloodborne entry as well as potential
neuroinvasion of peripheral and cranial nerves.79,80 With the
advent of improved technology such as polymerase chain
reaction (PCR) and real-time PCR, microbiome sequencing,
and monoclonal antibodies to very specific epitopes, unique
bacteria are being identified in the human population.81
Table 2 Proposed bacteria emerging in central nervous system
disease
Bacteria

Condition/disease
association

Bacterial
family

Orientia tsutsugamushi
Ehrlichia chaffeensis
Chlamydia pneumoniae

Meningitis
Meningoencephalitis
Alzheimer’s disease/
multiple sclerosis
Neuroborreliosis/
Alzheimer’s disease
Parkinson’s disease

Rickettsiaceae
Anaplasmataceae
Chlamydiaceae

Borrelia burgdorferi
Helicobacter pylori

Spirochaetaceae
Helicobacteraceae

Note: Although some of these organisms have been associated with acute and/
or chronic CNS disease entities, causality in numerous instances remains to be
proven.
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Intriguingly, many of these agents are being identified in
areas of the body not thought to be initially infected such
as the CNS and associated with chronic disease. Chronic
disorders, more so than ever before, are being attributed to
chronic infectious processes; emerging bacterial infection in
the CNS may follow a similar pattern.

Intracellular bacteria
Orientia tsutsugamushi

Orientia tsutsugamushi is an obligate intracellular pathogen
in the family Rickettsiaceae, and is the causative organism
of scrub typhus.82 The natural vector and reservoir is the
trombiculid mite.83 O. tsutsugamushi is a very common
infection in Southeast Asia and in the western Pacific Rim
countries. Because disease with this organism often presents
as a febrile illness, a number of studies have investigated
involvement with the CNS.80,84,85 The organism is thought
to gain access to the CNS following infection of circulating
monocytes and invasion of endothelial cells.80 Symptoms
following entry to the CNS include nuchal rigidity, seizures,
delirium, as well as meningismus and meningitis.80,84 In the
endemic area of scrub typhus, O. tsutsugamushi should be
considered a potential causative organism in mononuclear
cell–involved meningitis as greater recognition has been
demonstrated for the emergence of this Rickettsial organism
in CNS disease.85 Treatment for infections with O. tsutsugamushi typically includes using the antibiotics doxycycline
and/or azithromycin.86

Ehrlichia chaffeensis
Ehrlichia chaffeensis, an obligate intracellular bacterium
in the family Anaplasmataceae, causes human monocytic
ehrlichiosis (HME). HME rates of infection are estimated to
be 100–200 per 100,000 in endemic areas in the US, which
include87 Mississippi, Oklahoma, Tennessee, Arkansas, and
Maryland.88 Reports from other states are also being noted
suggesting a continual emergence in the US.89 Importantly,
as up to 66% of infections with E. chaffeensis are either
minimally symptomatic or asymptomatic, the exact incidence
of human infection may be higher.90 HME is transmitted
by infection with the tick vector, Amblyomma americanum
(Lone Star tick), which is prevalent in the southeast and
south-central regions of the US.91 Neurologic manifestations
occur in approximately 20% of patients infected with HME.
Some patients may experience cranial nerve palsy and cognitive deficits, and in children, there may be longer-term sequelae, including foot drop, fine motor impairment, and cognitive
change.92 Pathogenesis in HME infections appears to result
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from the inability of the cell to undergo phagolysosome
fusion,93 and to the immune-mediated pathology that results
especially with significant expansion of cytotoxic CD8+
T cells and their production of tumor necrosis factor-alpha
and interferon-gamma.94 Since 1987, HME has become a
serious and prevalent tick-borne cause of human infections
in the US.95 With the ever-expanding niche for ticks and
animal reservoirs such as white-tailed deer, and their increasing encounters with the resident human population, HME
will continue to emerge as a major cause of vector-borne
meningoencephalitis. Treatment for HME typically involves
a course of antibiotic therapy with doxycycline.96

Chlamydia pneumoniae
Chlamydia pneumoniae (Cpn), an obligate intracellular
bacterium in the family Chlamydiaceae, typically infects
the human respiratory tract often resulting in a chronic
cough, little sputum production, and a low-grade fever.97 The
organism has been shown to enter the systemic circulation
following infection of monocytes surveilling lung tissues.98
The ability to spread systemically may be one reason this
bacterium has been identified in nonrespiratory conditions,
including AD and multiple sclerosis (MS). Associations
of Cpn with AD99 and MS100 were first reported in 1998.
Over the last several years, other reports have strengthened
these associations,101,102 but more evidence is required
to demonstrate proof of causality. In this regard, studies
have addressed and continue to address Cpn infection in
vivo in diseased populations and in animal models, and in
vitro in infected tissue cultures. What is becoming clearer
is that Cpn can enter and remain in the CNS as a chronic/
persistent infection,103,104 and may be a major stimulus for
neuroinflammation.105 Furthermore, infection of the brain
may involve not only monocyte delivery but also infection
of the olfactory cranial nerve following exposure in the nose.
Evidence for this pathway follows from analysis of olfactory
tissues from patients with AD,99 as well as animal models.103
Molecular analyses following Cpn infection in cell culture
are addressing specific pathways known to be disrupted or
modified in AD. For example, modification of apoptosis106
and autophagy pathways as well as inflammatory pathways
following infection are being studied to better understand
the molecular pathogenesis of infection-mediated disease. In
effect, continued correlation of CNS infection with Cpn and
AD and MS may reflect the relatively newly recognized emergence of chronic infection with major neurological diseases.
Treatment for community-acquired pneumonias, including
those caused by Cpn, typically involves antibiotics such as
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doxycycline, azithromycin, and/or fluoroquinolones.107 One
clinical trial with some positive results has been performed
using the anti-Cpn antibiotics doxycycline and rifampin in
treating patients with AD.108

Extracellular bacteria
Borrelia burgdorferi

Borrelia burgdorferi organisms are spirochetes in the family
of Spirochaetaceae that cause borreliosis or Lyme disease,
a zoonotic, vector-borne disease transmitted primarily by
ticks such as Ixodes scapularis in North America. Typically,
a localized infection occurs following the tick bite, and
evasion of the immune system ensues once in the host.109
B. burgdorferi infects monocytes that are thought to disseminate the organism into the CNS through the blood-brain
barrier.109 Once the organism is in the brain, a chronic infection may ensue in which neuroborreliosis and/or Alzheimer’s
disease may become manifest.110 Symptoms of nervous
system involvement may include meningoradiculitis, cranial
nerve abnormalities, and altered mental status.109 Evidence
for involvement in AD comes from analysis of postmortem
AD brain tissues in which Borrelia was identified.111 Further
studies in vitro have supported these findings by demonstrating that infection of neurons, astrocytes, and microglial cells
led to the production and aggregation of amyloid as well as
tangle-like structures within nerve cells.112 In this regard,
bacterial products from the organism such as lipopolysaccharide have been shown to initiate a strong response by
neuronal and glial cells implicating Borrelia with AD.112
At this time, causality has not been determined regarding
this infection and AD pathogenesis; however, the infection
induction of beta amyloid processing and tau hyperphosphorylation comparable to what is observed in AD makes
B. burgdorferi a candidate infection as a stimulus for CNS
damage.112 Neuroborreliosis is typically treated with intravenous antibiotics that cross the blood-brain barrier such as
ceftriaxone and doxycycline.113

Helicobacter pylori
Helicobacter pylori are members of the Helicobacteraceae
family. Infection with this organism in the stomach is considered the major cause of peptic and gastric ulcers.114 H. pylori
infection has been postulated to play a role in idiopathic
Parkinson’s (IP) disease.115 This follows from analysis of
common immunological manifestations, epidemiological
similarities of familial aggregation and linkage with a common source of drinking water, and the demonstration that
the infection can be passed between siblings in childhood
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and between spouses.115 Probands with IP and siblings share
a threefold increase in odds of seropositivity for antibodies
against H. pylori urease.116 Furthermore, a discriminant index
for the presence/absence of diagnosed Parkinsonism has
been derived from Western blot serum H. pylori antibody
profiles in subjects with and without IP that contained known
pathogenicity markers.117 The persistence of antibody against
cytotoxin-associated antigen (CagA) increased the predicted
probability of Parkinsonism by 80 years of age fivefold.117
More recently, a population-based study of patients with
Parkinson’s in Denmark suggested chronic H. pylori infection and/or gastritis either contributed to Parkinson’s disease
(PD) or that these are PD-related pathologies that precede
motor dysfunction.118 Mechanistically, chronic inflammation and autoimmune modulation have been proposed as
contributors to IP with H. pylori infection.115 Some evidence
for immune modulation has been demonstrated in vitro as
H. pylori has been shown to suppress T-cell proliferation,119
and in infected individuals, H. pylori-specific T-regs have
been shown to suppress T-cell responses.120 Extraintestinal
influence in IP may be more prominent with CagA-positive
strains of H. pylori regarding autoimmune mechanisms.121
The exact relationship between H. pylori infection and IP
has yet to be determined. What is becoming clearer is that
relationships may exist between the gut and brain such that
infectious components arising in the gastrointestinal tract
affect brain function. Treatment for H. pylori gastric infection typically includes the combination of two antibiotics
such as clarithromycin and metronidazole and a proton pump
inhibitor such as omeprazole, sometimes together with a
bismuth compound.122

Conclusion
Emerging viruses and bacteria in the CNS are significant
contributors to increased morbidity and mortality in human
populations worldwide. Recognition of this emergence is
vital in developing adequate preventive regimens, diagnostic
procedures, and treatment measures. Clinicians and infectious
disease researchers must be aware of acute and chronic processes of infectious origin that may be insulting the nervous
system. Neurological diseases not typically thought to be
infectious must be examined fully for microbial involvement
and analyzed for direct and indirect associations. We are challenged to develop methodology that will clearly detect and
identify infectious agents in the CNS. Finally, understanding
the relationships between systemic infection and neurologic
disease is vital, and may provide clues leading to better predictability, treatment, and prevention of CNS diseases.
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